(RTTNews) – GSK plc (GSK.L, GSK) issued an update on the ContRAst phase III programme for otilimab, an investigational monoclonal antibody targeting granulocyte-macrophage colony-stimulating factor, in the potential treatment of moderate to severe rheumatoid arthritis. While the
Latest Article Feed


About the author

{"email":"Email address invalid","url":"Website address invalid","required":"Required field missing"}
New Market Highs - Protect Your Gains

Protect Yourself From Another Crash

How to protect profits against another crash